Enter assignee name

CIPO Patents = 2

EPO Patents = 2

Forward Citations = 612

Loading Chart...

2 inventors (with patents filed for the assignee):

Michael S Kopreski (21 out of 40 patents)

Christopher D Gocke (5 out of 25 patents)

Mike Kopreski (0 patent)

21 patents: Sort by Forward Citations

1. 8809020 - Method enabling the use of extracellular ribonucleic acid (RNA) extracted from plasma or serum to detect, monitor or evaluate cancer or premalignant conditions (2014-08-19),

2. 8440396 - Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer (2013-05-14),

3. 8163524 - Comparative analysis of extracellular RNA species (2012-04-24),

4. 8043835 - Methods for detecting and monitoring cancer using extracellular RNA (2011-10-25),

5. 8030031 - Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer (2011-10-04),

6. 7972817 - Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer (2011-07-05),

7. 7968317 - Detection of 5T4 RNA in plasma and serum (2011-06-28),

8. 7932061 - Method enabling the use of extracellular ribonucleic acid (RNA) extracted from plasma of serum to detect, monitor or evaluate cancer or premalignant conditions (2011-04-26),

9. 7910336 - Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum (2011-03-22),

10. 7785842 - Comparative analysis of extracellular RNA species (2010-08-31),

11. 7767423 - Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer (2010-08-03),

12. 7767422 - Detection of 5T4 RNA in plasma and serum (2010-08-03),

13. 7767390 - Methods for evaluating drug-resistance gene expression in the cancer patient (2010-08-03),

14. 7732141 - Methods for evaluating drug-resistance gene expression in the cancer patient (2010-06-08),

15. 7709233 - Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer (2010-05-04),

OncoMEDx, Inc. is a biotechnology company specializing in developing innovative solutions for cancer diagnosis and research. With a focus on precision medicine, the company aims to improve patient outcomes through advanced molecular testing and personalized treatment strategies. OncoMEDx's cutting-edge technologies enable healthcare professionals to make informed decisions and tailor therapies based on genetic and molecular profiles. Through its integrated platform and proprietary algorithms, OncoMEDx strives to revolutionize cancer care by providing accurate, reliable, and fast diagnostic solutions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

21 Patents

#2 in Long Valley, NJ

#603 in New Jersey

#15,187 in US

#29,088 in the World

Long Valley, NJ, United States of America

Oncomedx, Inc.

Forward Citations = 612

2 inventors:

Michael S Kopreski (21 out of 40 patents)

Christopher D Gocke (5 out of 25 patents)

Mike Kopreski (0 patent)

Please report any incorrect information to support@idiyas.com